KKKawinthra Khwanraj

Kawinthra Khwanraj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kawinthra Khwanraj has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Athinan Prommahom

    Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand, mahidol.ac.th

    1 shared publication
  • Athinan Prommahom

    Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University Samut Prakan Thailand

    1 shared publication
  • Atipha Kijkraikul

    Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

    1 shared publication
  • Chonlakorn Panyasuppakun

    Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

    1 shared publication
  • Permphan Dharmasaroja

    Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

    1 shared publication
  • Permphan Dharmasaroja

    Department of Anatomy, Faculty of Science, Mahidol University, Bangkok, Thailand

    1 shared publication

Latest Publications

  • Open Access

    The Multifaceted Roles of Eukaryotic Elongation Factor 1‐Alpha‐2 in Neurodevelopmental and Neurodegenerative Disorders

    by Kawinthra Khwanraj, Athinan Prommahom, Permphan Dharmasaroja

    Eukaryotic elongation factor 1‐alpha‐2 (eEF1A2) is a neuron‐ and muscle‐specific translation elongation factor isoform that supports high‐demand proteostasis in terminally differentiated cells. Beyond its canonical role in translation elongation, eEF1A2 participates in noncanonical processes linked to actin cytoskeleton regulation, compartmentalized/local translation, and stress–response signaling. A central challenge in the field is that the strength and type of evidence implicating eEF1A2 differ substantially across disease classes. In neurodevelopmental disorders, heterozygous de novo pathogenic variants in EEF1A2 provide strong causal human genetic evidence for developmental and epileptic encephalopathies and related phenotypes, supported by functional studies showing reduced de novo protein synthesis/elongation and altered actin bundling in common patient‐associated variants. In contrast, in neurodegenerative paradigms (e.g., toxin‐based Parkinson′s disease models and ischemia‐reperfusion injury), eEF1A2 is primarily implicated as a contributory node within oxidative stress, autophagy/mitophagy, and inflammatory signaling pathways, largely based on cellular and animal model evidence rather than Mendelian causality. This review adopts an evidence‐based framework and organizes findings around a unified mechanistic model connecting canonical elongation and noncanonical cytoskeleton/stress/autophagy functions to neuronal phenotypes. Collectively, current evidence supports a causal role for eEF1A2 in neurodevelopmental disorders but only a contributory role in neurodegenerative conditions.


  • Open Access

    Neuroprotective Effects of Asiatic Acid on Autophagy and Mitochondrial Integrity in a Parkinson’s Disease Cellular Model

    by Athinan Prommahom, Tatcha Balit, Sunisa Somkana, Satjapot Manprasong, Chonlakorn Panyasuppakun, Atipha Kijkraikul, Preawanit Thawornrungroaj, Pitchaya Thawornrungroaj, Permphan Dharmasaroja, Thanasup Gonmanee, et al.

    Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder. PD patients mostly exhibit mitochondrial dysfunction and autophagic impairment. Asiatic acid (AA) is a triterpenoid with the highest antioxidant activity used to treat oxidative stress. It has been found to have a neuroprotective effect against mitochondrial dysfunction in cellular models of PD; however, its effect on autophagy has not been investigated. Purpose: This study aimed to investigate whether AA affects autophagy in a cellular model of PD. Methods: SH-SY5Y cells were differentiated into dopaminergic neuron-like cells via retinoic acid administration. Differentiated cells were treated with AA for 24 h and then exposed to 1-methyl-4-phenylpyridinium (MPP+). Cell viability was assessed using a 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay. The expression of microtubule-associated protein 1 light chain 3 (LC3)-II/I, Beclin-1, sequestosome-1/ubiquitin-binding protein p62 (SQSTM1/p62), and tyrosine hydroxylase (TH) was analyzed via Western blot. Caspase-3/7 and LC3 expression was measured using immunofluorescence, as was the colocalization of LC3 and mitochondria. MitoTracker and JC-10 were used to assess the mitochondrial morphology and mitochondrial membrane potential (ΔΨm), respectively. Results: Pretreating cells with AA before MPP+ exposure resulted in significantly higher expression of LC3-II/I and Beclin-1, while the expression of SQSTM1/p62 was slightly lower compared to that in cells not pretreated with AA. Cells pretreated with AA exhibited significantly higher viability and TH expression, but significantly lower caspase-3/7 expression and numbers of apoptotic nuclei compared to cells treated with MPP+ alone. Notably, pretreatment with AA resulted in tubular mitochondria with considerably higher ΔΨm values. The colocalization of LC3 and mitochondria was also significantly higher in the cells pretreated with AA. Conclusion: AA protected dopaminergic neuron-like cells against MPP+-induced apoptosis via the induction of autophagy and the enhancement of mitochondrial function, suggesting that it could be developed as a therapeutic agent for PD.